Pulmonary Embolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Pulmonary embolism pipeline market research report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.
Key Targets in the Pulmonary Embolism Pipeline Market
The key targets in the pulmonary embolism pipeline market are Plasminogen, Coagulation Factor X, Coagulation Factor XI, Platelet Glycoprotein VI, Prothrombin, and Urokinase Type Plasminogen Activator. Plasminogen has the highest pipeline products.
Pulmonary Embolism Pipeline Market, by Target
For more target insights, download a free report sample
Key MoA in the Pulmonary Embolism Pipeline Market
The key MoA in the pulmonary embolism pipeline market are Plasminogen Activator, Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Platelet Glycoprotein VI Inhibitor, Prothrombin Inhibitor, and Urokinase Type Plasminogen Activator Replacement. Plasminogen Activator has the highest number of pipeline products.
Pulmonary Embolism Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Pulmonary Embolism Pipeline Market
The key RoA in the pulmonary embolism pipeline market are intravenous, oral, subcutaneous, topical, and transdermal. Intravenous has the highest number of pipeline products.
Pulmonary Embolism Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Pulmonary Embolism Pipeline Market
The key molecule types in the pulmonary embolism pipeline market are recombinant enzyme, monoclonal antibody, and small molecule. Recombinant enzyme has the highest number of pipeline products.
Pulmonary Embolism Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the Pulmonary Embolism Pipeline Market
The key companies in the pulmonary embolism pipeline market are Acticor Biotech SAS, Anthos Therapeutics Inc, Bio-Synectics Inc, China Resources Emde Biological Pharmaceutical Co Ltd, Indiana Lysis Technologies LLC, Kolmar Korea Co Ltd, Supergene LLC, Tasly Pharmaceutical Group Co Ltd, Techfields Pharma Co Ltd, Tianjin Pharmaceuticals Group Co Ltd, and Verseon Corp.
Market report overview
Key targets | Plasminogen, Coagulation Factor X, Coagulation Factor XI, Platelet Glycoprotein VI, Prothrombin, and Urokinase Type Plasminogen Activator |
Key MoA | Plasminogen Activator, Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Platelet Glycoprotein VI Inhibitor, Prothrombin Inhibitor, and Urokinase Type Plasminogen Activator Replacement |
Key RoA | Intravenous, Oral, Subcutaneous, Topical, and Transdermal |
Key molecule types | Recombinant Enzyme, Monoclonal Antibody, and Small Molecule |
Key companies | Acticor Biotech SAS, Anthos Therapeutics Inc, Bio-Synectics Inc, China Resources Emde Biological Pharmaceutical Co Ltd, Indiana Lysis Technologies LLC, Kolmar Korea Co Ltd, Supergene LLC, Tasly Pharmaceutical Group Co Ltd, Techfields Pharma Co Ltd, Tianjin Pharmaceuticals Group Co Ltd, and Verseon Corp |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Anthos Therapeutics Inc
Bio-Synectics Inc
China Resources Emde Biological Pharmaceutical Co Ltd
Indiana Lysis Technologies LLC
Kolmar Korea Co Ltd
Supergene LLC
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Verseon Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the pulmonary embolism pipeline market?
The key targets in the pulmonary embolism pipeline market are Plasminogen, Coagulation Factor X, Coagulation Factor XI, Platelet Glycoprotein VI, Prothrombin, and Urokinase Type Plasminogen Activator.
-
What are the key MoA in the pulmonary embolism pipeline market?
The key MoA in the pulmonary embolism pipeline market are Plasminogen Activator, Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Platelet Glycoprotein VI Inhibitor, Prothrombin Inhibitor, and Urokinase Type Plasminogen Activator Replacement.
-
What are the key RoA in the pulmonary embolism pipeline market?
The key RoA in the pulmonary embolism pipeline market are intravenous, oral, subcutaneous, topical, and transdermal.
-
What are the key molecule types in the pulmonary embolism pipeline market?
The key molecule types in the pulmonary embolism pipeline market are recombinant enzyme, monoclonal antibody, and small molecule.
-
What are the key companies in the pulmonary embolism pipeline market?
The key companies in the pulmonary embolism pipeline market are Acticor Biotech SAS, Anthos Therapeutics Inc, Bio-Synectics Inc, China Resources Emde Biological Pharmaceutical Co Ltd, Indiana Lysis Technologies LLC, Kolmar Korea Co Ltd, Supergene LLC, Tasly Pharmaceutical Group Co Ltd, Techfields Pharma Co Ltd, Tianjin Pharmaceuticals Group Co Ltd, and Verseon Corp.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.